Abstract: There are described mononuclear copper complexes having anti-inflammatory activity. The complexes include copper complexes of indomethacin. There are also provided methods for the prophylaxis or treatment of inflammation comprising administering such complexes to a mammalian subject.
Type:
Application
Filed:
March 24, 2006
Publication date:
February 12, 2009
Inventors:
Peter Lay, Trevor Hambley, Brenden Kennedy, Ying Morgan
Abstract: The present invention provides novel mechanisms that regulate the production of anti-inflammatory and pro-inflammatory mediators generated by 5-lipoxygenase. In this regard, the present invention establishes that phosphorylation of 5-Lipoxygenase by protein kinase A, has a crucial role in determining the end products of 5-Lipoxygenase. With translocation to the nucleus, potent proinflammatory leukotrienes are produced, whereas following phosphorylation by protein kinase A, anti-inflammatory mediators are produced. The present invention also discloses compounds that regulate these pro- and anti-inflammatory mediators.
Abstract: The invention is an antimicrobial photo-stable coating composition that deters photo-induced discoloration, does not stain tissue and can be applied to the surface of a variety of medical materials. The composition comprises in an aspect silver-PCA complex and dye.
Type:
Application
Filed:
July 31, 2008
Publication date:
February 5, 2009
Inventors:
Vyacheslav Dudnik, Yakeemovich Natali, Valerio DiTizio, Frank DiCosmo
Abstract: The present invention relates to methods and compositions for rendering a surface resistant to bio-film formation by a combination of an alkanediol and an antimicrobial agent (and, optionally, an organic hydroxy acid). The invention provides for compositions which may be used to render surfaces bio-film resistant, articles having bio-film resistant surfaces, and methods for their preparation. The present invention may be advantageously applied to medical articles as well as articles used in non-medical contexts, such as child care or food preparation.
Type:
Application
Filed:
June 6, 2008
Publication date:
January 29, 2009
Inventors:
Shanta M. Modak, Lauserpina A. Caraos, Ronald Citron, Ingrid Geraldo
Abstract: This invention relates to methods and systems for providing a prognosis to a subject on developing vasospasm as a results of hemorrhagic event, and compounds and compositions for treatment thereof. Specifically, the invention relates to the use of haptoglobin genotyping in the prognosis of the development of vasospasm following SAH, and antioxidants such as glutathione peroxidase mimetics for treatment.
Abstract: The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.
Type:
Application
Filed:
September 10, 2008
Publication date:
January 8, 2009
Applicant:
The General Hospital Corporation
Inventors:
David R. Elmaleh, Timothy M. Shoup, Alan J. Fischman
Abstract: The invention provides a biological dressing for treatment of a dermatological disease comprised of one or more resins or other film-forming agents, a topically acceptable volatile solvent, and a pharmacologically active agent. The combined one or more resins are present in a suitable amount such that the composition, when the solvent evaporates, will dry to form a solid coating that sticks to the skin, nail or mucosal membrane to which the composition is applied, and maintain the pharmacologically active agent over a sustained period of time in contact with sites on the skin or mucosal membranes exhibiting symptoms of the disease. Methods are provided for treating symptoms of dermatological diseases with such a pharmacological composition.
Abstract: Methods of using methotrexate (MTX) active agents in which reduced host toxicity is observed are provided. In the subject methods, an effective amount of an MTX active agent is administered to the host in conjunction with the administration of an MTX toxicity reducing agent of the present invention. Also provided are compositions for use in practicing the subject methods, e.g., pharmaceutical compositions having reduced toxicity, in which the MTX active agent is combined with an MTX toxicity reducing agent that reduces the level of undesired MTX toxicity while maintaining an effective MTX anti-proliferative activity. Also provided are methods of using the subject methods and compositions in the treatment of a variety of different disease conditions.
Abstract: Disclosed are anti-viral compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating lesionous symptoms of a viral infection involving applying an effective amount of the anti-viral composition to the lesions.
Abstract: A method of forming an iron hydroxypyrone compound comprising reacting an iron salt of a carboxylic acid and a hydroxypyrone in an aqueous solution at a pH greater than 7.
Abstract: Provided are ophthalmic pharmaceutical compositions comprising gallium. These compositions are designed primarily for topical ocular and intraocular administration. Also provided are methods of use for the compositions in the treatment of human and veterinary diseases and disorders. Treatable diseases and disorders include adverse conditions of the eye and adnexal tissues of the eye. These adverse conditions comprise inflammatory conditions, infections, cancers, and other pathological conditions.
Abstract: The invention relates to combination comprising a pharmaceutically acceptable preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a gallium and its use in diagnosis. The invention also pertains to the use of a compound of formula I or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of an excess iron overload in the human or animal body whereby said body is undergoing gallium scintigraphy and whereby the treatment removing said excess of iron is interrupted for a period of 2 to 10 days prior to the gallium scintigraphy and resumed after the gallium scintigraphy readings.
Abstract: Disclosed herein is a method for protecting humans in need of such protection from physical damage caused by ionizing radiation comprising administering to said humans on a defined basis prior to and after exposure to such radiation a plurality of antioxidants at a dosage level directly proportional to the radiation level likely to be encountered.
Type:
Grant
Filed:
August 28, 2002
Date of Patent:
November 11, 2008
Assignee:
Premier Micronutrient Corporation
Inventors:
Kedar N. Prasad, Gerald M. Haase, William C. Cole
Abstract: An antimicrobial and chemical deactivating composition for use in a liquid medium or for incorporation into a coating, structural plastic materials, thin microporous membranes, textiles and sponges. The composition includes macrosize or submicron particles of silver, platinum with silver and their salts with parabens, oxide, salicylate, acetate, citrate, benzoate and phosphate along with copper and zinc salts of the same.
Abstract: A method for inhibiting microbial growth comprises administering an effective amount of a silver complex of a N-heterocyclic amine. A method for treating cancer cells or a method for imaging one or more tissues of a patient includes administering an effective amount of a complex of a N-heterocyclic amine and a radioactive metal. N-heterocyclic carbenes of the present invention may be represented by formula (I) wherein Z is a heterocyclic group, and R1 and R2 are, independently or in combination, hydrogen or a C1-C12 organic group selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, arylalkyl, alkylaryl, heterocyclic, and alkoxy groups and substituted derivatives thereof.
Type:
Application
Filed:
September 7, 2004
Publication date:
October 30, 2008
Inventors:
Wiley J. Youngs, Claire A. Tessier, Jared Garrison, Carol Quezada, Abdulkareem Melaiye, Matthew Panzner, Semih Durmus
Abstract: Methods are provided for purifying marine collagen and for processing the collagen into porous sponges. Products produced with these methods and the use of the products are also provided.
Type:
Application
Filed:
February 14, 2006
Publication date:
October 23, 2008
Applicant:
LOHMANN & RAUSCHER GMBH & CO. KG
Inventors:
Corneliu Iulian Alupei, Peter Ruth, Christian Rohrer, Wolfgang Schatton
Abstract: Free radicals and reactive oxygen species have the potential to damage a wide variety of organic molecules, typically by oxidizing certain moieties. These damaging species can, for example, be produced by an organism as a by-product of cellular respiration or by the reaction of iron(II) and peroxide. The present invention includes methods of using aryl-substituted heterocyclic iron chelating compounds as antioxidants, as well as preventing the reduction of iron(III) to iron(II). In addition, the present invention provides methods of treating conditions such as inflammatory disease, neoplastic disease, and ischemic episodes.
Type:
Application
Filed:
March 27, 2008
Publication date:
October 16, 2008
Applicant:
University of Florida Research Foundation, Inc.
Abstract: This invention relates to the use of a combination of selected substances in paint to prevent the settlement and growth of different biofouling organisms with a reduced negative effect on the ecosystems compared to present methods.
Abstract: Methods for treating disease states in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide are provided. Methods for alleviating the symptoms of a disease state in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide in the subject are also provided. Pharmaceutical compositions comprising cobinamide and a pharmaceutically acceptable carrier are also provided.
Type:
Application
Filed:
June 17, 2005
Publication date:
September 18, 2008
Inventors:
Gerry Boss, Vijay Sharama, Kate E. Broderick
Abstract: This invention concerns antimicrobial compositions that are useful for industrial applications. More specifically, it concerns antimicrobial compositions that, by combining 3-benzo[b]thiene-2-yl-5,6-dihydro-1,4,2-oxathiazine-4-oxide and one or more of 1-[[(3-iodo-2-propynyl)oxy]methoxy]-4-methoxy benzene, 1-chloro-4-[[(3-iodo-2-propynyl)oxy]methoxy] benzene, Zinc 2-pyridine thiol-1-oxide, Copper 2-pyridine thiol-1-oxide, 2-pyridine thiol-1-oxide sodium salt, 2,2-dithio-bis(pyridine-1-oxide), 2-methylthio-4-t-butyl amino-6-cyclopropyl amino-s-triazine, 3-iodo-2-propynyl butylcarbamate (IPBC), 2-(n-octyl)-3(2H)-isothiazolone (OIT), 4,5-dichloro-2-(n-octyl)-3(2H)-isothiazolone (DCOIT), 2,4,5,6-tetrachloro-1,3-benzenedicarbonitrile (chlorothalonil), 1,1-dichloro-N-[(dimethylamino)sulfonyl]-1-fluoro-N-phenyl-methanesulfenamide (dichlofluanid), or 1,1-dichloro-N-[(dimethylamino)sulfonyl]-1-fluoro-N-(4-methylphenyl)-methanesulfenamide (tolylfluanid) have the synergistic effect of these compounds.
Abstract: The present invention relates to the use of zinc complexes of natural amino acids, especially L-arginine, L-lysine, L-ornithine, and other natural amino acids, in a molar ratio of about 1:2 (metal:amino acid), and formulations thereof. These pharmaceutical compositions offer better tolerated and faster acting regimens than common zinc salts (i.e., acetate, sulfate, etc.) for long term maintenance therapy of diseases caused by abnormal elevated copper levels, such as in Wilson's disease, inflammatory and fibrotic diseases and Alzheimer's disease.
Abstract: An anticancer agent containing platinum preparation, humic substances, water and sodium chloride. Potassium tetrachloroplatinate is used as a platinum compound and lignohumic acid ammonium salts are used as humic substances taken in the following ratio of components per 1 ml of solution: lignohumic acid ammonium salts 0.18-0.22 mg potassium tetrachloroplatinate 0.020-0.040 mg sodium chloride isotonic solution 0.97-0.99 ml distilled water up to 1.
Abstract: The invention provides multi-nuclear metal complexes partially encapsulated by one or more cucurbit[7 to 12]urils or analogues thereof. The invention further relates to methods for treating cancer by administering a multi-nuclear metal complex having anti-tumour activity partially encapsulated by one or more cucurbit[7 to 12]urils or analogues thereof.
Type:
Application
Filed:
January 14, 2005
Publication date:
July 31, 2008
Applicant:
NEWSOUTH INNOVATIONS PTY LIMITED
Inventors:
Nial Joseph Wheate, Anthony I. Day, Rodney J. Blanch, John G. Collins
Abstract: The present invention is generally directed to a method of prophylaxis against viral infection of a cell or subject or a method of treating a subject infected with a virus including administering an antiviral composition having the general Structure III, wherein each of R1, R2, R3, R4, R5 and R6 is the same or different and includes an N-based ligand donor atom selected from the group consisting of ammonia, primary amine or secondary amine, or salt thereof. The present invention is also generally directed to a method of preparing an antiviral agent including providing a cobalt pentammine salt having a non-amine coordination site and mono-substituting the non-amine coordination site with a functional group incorporating a strong coordinator atom to cobalt to form a CoHex structure of Structure III, in which R1 incorporates the functional group having the strong coordinator atom coordinated with the cobalt atom, or a salt thereof.
Type:
Application
Filed:
November 2, 2007
Publication date:
July 31, 2008
Applicant:
The Government of the US, as represented by the Secretary of the Navy
Inventors:
Eddie L. Chang, James B. Delehanty, Dzung C. Thach, Jason Bongard, Andy Knight
Abstract: Provided are ophthalmic pharmaceutical compositions comprising gallium. These compositions are designed primarily for topical ocular and intraocular administration. Also provided are methods of use for the compositions in the treatment of human and veterinary diseases and disorders. Treatable diseases and disorders include adverse conditions of the eye and adnexal tissues of the eye. These adverse conditions comprise inflammatory conditions, infections, cancers, and other pathological conditions.
Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.
Type:
Application
Filed:
August 12, 2007
Publication date:
July 17, 2008
Inventors:
Mark B. Roth, Mike Morrison, Eric Blackstone, Dana Miller
Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.
Type:
Application
Filed:
August 10, 2007
Publication date:
July 17, 2008
Inventors:
Mark B. Roth, Mike Morrison, Eric Blackstone, Dana Miller
Abstract: The invention is directed to formulations comprised of multiple dietary and endogenously made antioxidants and B-vitamins and the use of these formulations in preventing and treating coronary artery disease.
Type:
Grant
Filed:
February 17, 2006
Date of Patent:
July 15, 2008
Assignee:
Premier Micronutrient Corporation
Inventors:
Kedar N. Prasad, William C. Cole, Gerald M. Haase
Abstract: The present invention is related to a novel method for oxidizing or splitting nucleic acids at specific points on a complementary nucleic acid segment using a dinuclear copper-based compound of Formula I. Additionally, the present invention is related to a novel treatment of cancer, tumors, and cancer cells using a dinuclear copper-based compound of formula I or a naked ligand of Formula II.
Type:
Grant
Filed:
November 12, 2002
Date of Patent:
June 24, 2008
Assignees:
The University of Maryland, The Johns Hopkins University
Inventors:
Steven E. Rokita, Kenneth D. Karlin, Lei Li, Narasimha N. Murthy
Abstract: The present invention relates to a composition for use as an antimicrobial medicament comprising a biocidally active compound. The invention also relates to a medicament comprising at least one biocidally active compound and a fungal cell or fungal cell fragment wherein molecules of the at least one biocidally active compound are encapsulated or partially encapsulated by the fungal cell or fungal cell fragment.
Type:
Application
Filed:
January 18, 2005
Publication date:
June 12, 2008
Inventors:
Rachael Buck, Michael Edward Donald Crothers, Gordon Nelson
Abstract: Formulations for minimizing damage to at least one of cells, organs and systems within the body of a subject afflicted with Diabetes Mellitus. The invention additionally encompasses methods for minimizing said damage which comprise administering to subjects in need thereof a therapeutic amount of a formulation(s) according to the invention.
Type:
Application
Filed:
November 20, 2007
Publication date:
May 22, 2008
Inventors:
Kedar N. Prasad, William C. Cole, Gerald M. Haase
Abstract: A tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate-isothiocyanate at one isocyanate or isothiocyanate group thereof, the other isocyanate or isothiocyanate group being itself derivatised by addition reaction with the hydroxy group of an w-alkylated or acylated poly(alkylene oxide) or to a hydroxy group of a link residue itself carrying a residue of such poly(alkylene oxide).
Abstract: Supramolecular complexes that target and cleave DNA are provided. The supramolecular complexes include at least one metal-to-ligand charge transfer (MLCT) light absorbing unit, at least one Pt based DNA binding unit, and at least one bridging unit that serves to connect the components. The Pt-based DNA binding unit binds the complex to DNA, and the MLCT unit absorbs light, thereby sensitizing molecular oxygen to produce reactive oxygen species in close proximity to the complex and the bound DNA. The reactive oxygen species cleave the bound DNA.
Abstract: An allergen decomposer which contains as an active ingredient a derivative of metal phthalocyanine represented by the following formula (I) (M is a metal selected among iron, cobalt, manganese, titanium, vanadium, nickel, copper, zinc, molybdenum, tungsten, and osmium).
Abstract: A series of organometallic complexes and the singlet oxygen sensitization properties of these complexes are provided. Complexes with acetylacetonate ligands give singlet oxygen quantum yields near unity, whether exciting the ligand-based state or the lowest energy excited state (MLCT+3LC). The singlet oxygen quenching rates for these ?-diketonate complexes are small, roughly three orders of magnitude slower than the corresponding phosphorescence quenching rate. Similar complexes were prepared with glycine or pyridine tethered to the Ir(III) center (i.e. (bsn)2Ir(gly) and (bt)2Ir(py)Cl, where gly=glycine, and py=pyridine). The glycine and pyridine derivatives give high singlet oxygen yields.
Type:
Grant
Filed:
August 6, 2004
Date of Patent:
May 6, 2008
Assignee:
University of Southern California
Inventors:
Mark E. Thompson, Peter I. Djurovich, Drew Murphy, Matthias Selke
Abstract: The embodied composition is an evening dose of bio-identical hormones in a solvent with a vasodilator, a hormone modulator, and a carrier for balancing and maintaining Cortisol level in a human. The evening dose comprises progesterone ranging from 0.005 wt % to 41 wt %; pregnenolone ranging from 0.005 wt % to 41 wt %; ethoxydiglycol ranging from 0.005 wt % to 10 wt %; pentoxifylline ranging from 0.005 wt % to 10 wt %; ginseng ranging from 0.005 wt % to 41 wt %, and carrier q.s. Embodied herein is a method for balancing and maintaining Cortisol levels in humans by identifying the hormonal needs for a human, testing to ascertain the current relationship between of hormone levels, inserting the values of each hormone level into a hormone tree, balancing the hormones to a normal level, adjusting the levels for symptoms and sex type, and forming a resultant composition.
Abstract: A time release composition is provided containing: a chromium complex having formula 3 [Cr3O(carboxylate)6(ligand)3]+??(3) wherein carboxylate is a C2-C5 alkyl carboxylate and wherein ‘ligand’ is a ligand that (i) renders the chromium complex insoluble or only slightly soluble in water and (ii) is acid labile, being readily displaced under acidic conditions below pH=4 and replaced by water to make the resulting water soluble complex 2 [Cr3O(carboxylate)6(H2O)3]+,??(2) and the use of the time release composition for the time release delivery of complex 2.
Abstract: A method for the direct or adjunct treatment of bacterial or fungal infections in fish and crustaceans including shell fish which is based on providing an effective amount of an organic tellurium compound in an aqueous environment to which said fish or crustaceans are exposed.
Type:
Application
Filed:
December 9, 2004
Publication date:
March 27, 2008
Inventors:
Benjamin Sredni, Michael Albeck, Rami R. Avtalion, Eitan Okun
Abstract: Compositions, containing a ruthenium(III) complex and a heterocycle, methods for their manufacture, medicament containing these compositions and a kit. The invention relates to a composition (A), obtained by reacting a compound of the general formula (I) M3?n?p?2pr[RuX6?n?p?q?2rBn(H2O)p(OH)q(O)r]2r+1??(I) with a compound of the general formula (II) B?(HX?)S.??(II) Furthermore, the invention relates to a composition (B), obtained by mixing a compound of the general formula (III) (B?H)3?n?p?2pr[RuX6?n?p?q?2rBn(H2O)p(OH)q(O)r]2r+1??(III) with a compound of the general formula (IV) MX?.
Type:
Grant
Filed:
July 25, 2003
Date of Patent:
March 4, 2008
Assignee:
Faustus Forschungs Cie. Translational Cancer Research GmbH
Abstract: 1) Fungicidal compositions comprising: a) at least one pyridylmethylbenzamide derivative of formula (I), in which the various radicals are as defined in the description, and b) at least one compound (II) chosen from dithiocarbamates, preferably fungicidal dithiocarbamates, and, still more preferably from the following active agents: ferbam, mancopper, mancozeb, maneb, metiram, nabam, nickel bis(dimethyldithio-carbamate), propineb, zineb and mixtures thereof; and their agriculturally acceptable isomers and addition salts with an acid. 2) Method for the curative or preventive control of phytopathogenic fungi of crops using an effective and non-phytotoxic quantity of one of these fungicidal compositions.
Abstract: A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as catalysts or “pseudo” enzymes for the oxidation. These additives include multivalent transition metal ions, as well as complexes thereof, and NAD+ which enhance the oxidation reaction. The method described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.
Abstract: A composition for the treatment of Herpes Labialis which contains CTC-96 as the active ingredient is disclosed. Methods for using the composition are also disclosed. The composition may be used as a topical ointment.
Abstract: This invention relates to the use of a combination of selected substances in paint to prevent the settlement and growth of different biofouling organisms with a reduced negative effect on the ecosystems compared to present methods.
Abstract: The invention provides a liposome composition for delivering high pay-load of a therapeutic agent to neovascularization sites of the eyes in a patient in need thereof. The liposome composition for entrapping the therapeutic agent comprises a particle forming component composed of a variety of vesicle-forming lipids, and an agent-carrying component able to form a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction; wherein the liposome composition comprising the therapeutic agent has a mean particle diameter of about 30 to 200 nm and may accumulate at the neovascularization sites of the eyes 24 hours after the intravenous administration of the liposome composition comprising the therapeutic agent to the patient.
Type:
Application
Filed:
May 23, 2006
Publication date:
November 29, 2007
Applicants:
TAIWAN LIPOSOME CO. LTD., TLC BIOPHARMACEUTICALS, INC.
Inventors:
Jun-Jen LIU, Chi-Chun Lai, Yun-Long TSENG, Luke S.S. GUO, Keelung HONG
Abstract: A method of enhancing a mineral level in an animal with reduced environmental impact can comprise orally administering a metal amino acid chelate to an animal, wherein the amino acid to metal molar ratio of the metal amino acid chelate is from about 1:1 to 4:1. The metal can contribute to a mineral level within the blood and tissues of the animal that is effective for stimulating growth of the animal to a greater degree than would be realized by administering the same amount of metal in the form of an inorganic metal salt. Additionally, the amount of the metal excreted in the feces of the animal can be less than would be present when administering the same amount of metal in the form of the inorganic metal salt. The metal amino acid chelate can also serve as a source highly bioavailable amino acids, so that the excretion of nitrates by the animal may be reduced while still promoting efficient growth.
Abstract: Topical preparation dispensers and methods of using the same are provided. Aspects of the invention include a topical preparation dispenser having a holder, one or more vertically stacked topical preparations in the holder, and a cap at one end of the holder configured such that upon movement of the cap, a topical preparation is exposed and moved relative to the holder. Also provided are kits that include the subject dispensers.
Abstract: A cosmetic composition for use as scrubbing agent or a mask uses vitamin C particles or crystals in an oil base, whereby the particles are insoluble in the oil so that they remain as suspended scrubbing particles.
Abstract: The present invention concerns the use of methods and compositions for the treatment of cancer and other hyperproliferative diseases. In certain embodiments, methods are described for the treatment of cancer and/or hyperproliferative diseases by administration of compositions containing at least one platinum complex alone or in combination with a modulator of glutathione. In particular, the methods may be used to treat cisplatin or carboplatin resistant tumor cells.
Type:
Grant
Filed:
September 5, 2003
Date of Patent:
September 18, 2007
Assignee:
Board of Regents, the University of Texas System